Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

शेयरों में रैंक #3091
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
शेयर मूल्य
$93.69
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$5.89B
बदलाव (1 दिन)
2.56%
बदलाव (1 वर्ष)
393.11%
देश
US
व्यापार Kodiak Sciences Inc. (KOD)

श्रेणी

Healthcare
Kodiak Sciences Inc. (KOD) के लिए P/S अनुपात
October 2026 को P/S अनुपात TTM: 0.00
Kodiak Sciences Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/S अनुपात (TTM) 0.00 है। 2023 के अंत में, कंपनी का P/S अनुपात 0.00 था।
Kodiak Sciences Inc. के लिए 2016 से 2026 तक P/S अनुपात का इतिहास
हर वर्ष के अंत में P/S अनुपात
वर्ष P/S अनुपात परिवर्तन
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए P/S अनुपात
कंपनी P/S अनुपात P/S अनुपात में अंतर देश
10.02 -
US
40.55 -
US
3.96 -
AU
- -
CH
10.15 -
NL